PSA can be elevated for reasons other than cancer (like benign enlargement or inflammation). That uncertainty can lead to “just in case” biopsies.
PHI combines three biomarkers into a single score that better stratifies risk in men who are being evaluated for possible prostate cancer. Used appropriately, it can help increase confidence when deciding whether biopsy is warranted.
ProstateGuard is built for conversations between patients and clinicians—helping many patients confidently avoid an unnecessary prostate biopsy while ensuring higher-risk cases get timely follow-up.